MAIA Biotechnology stockholders re-elect directors, ratify auditor, approve equity plan amendment

MAIA Biotechnology, Inc.

Re-elected Class I directors Louie Ngar Yee and Steven Chaouki with >6M votes each; 352k broker non-votes.
Ratified Grant Thornton as independent auditor for FY2023: 6,502,742 for, 3,091 against, 63 abstain.
Approved amendment to 2021 Equity Incentive Plan allowing annual share increase of 10% of fully diluted outstanding through 2032.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MAIA Biotechnology, Inc. shareholders approved Election of Class I directors for three-year terms expiring in 2026 at the 2023-05-25 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-05-25

Exact text from the filing

Stockholders re-elected both of the Company’s Class I nominees for director for three-year terms expiring on the annual meeting of stockholders to be held in 2026 or until their successors are duly elected and qualified

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MAIA Biotechnology, Inc. shareholders approved Ratification of appointment of Grant Thornton LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-05-25 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-05-25

Exact text from the filing

Stockholders ratified the appointment of Grant Thornton LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

MAIA Biotechnology, Inc. shareholders approved Amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan to include automatic annual increase in shares reserved at the 2023-05-25 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-05-25

Exact text from the filing

Stockholders approved an amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the “2021 Plan” ) to include an automatic increase in the aggregate number of shares reserved for awards under the 2021 Plan

View on SEC.gov

63 shareholder votes filed in the last 30 days. Browse all shareholder votes →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-23-007471

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.